Pricing drugs, selling hype and how we got here in the first place
FierceBiotech chats with a pair of lawyers about how drug pricing is unique in the U.S. and how the biopharma environment lends itself to se...
Radio and PodcastLive Radio & Podcasts
Science & Medicine
FierceBiotech Radio
FierceBiotech brings you interviews and analysis from around the biotech, pharma and medical device industries.
Episodes
20 of 43 episodes
The FierceMadness drug name showdown and how do drugs get their zany names anyway?
Fierce editors discuss the 2018 FierceMadness drug name tournament, its origins, and our favorites heading into the competition, while Scott...
Back from the dead: FierceBiotech Radio at the Battle of the Biotech Bands
FierceBiotech Radio rose from the grave for this special Halloween episode where we sat down with some of the scientists, account associates...
GSK's CEO shakeup, Lilly's Alzheimer's uncertainty, and Valeant's latest disaster
Fierce editors discuss the pending retirement of GlaxoSmithKline CEO Andrew Witty, Eli Lilly's bold decision with a big Alzheimer's trial an...
The FDA's new boss, Sanofi's latest shortcut, and a little 'financial innovation'
Fierce editors discuss the confirmation of Robert Califf as the next FDA commissioner, Sanofi's efforts to undercut Novo Nordisk in diabetes...
Pharma's TV blitz, biotech's IPO trickle, and the M&A future of Intercept Pharmaceuticals
Fierce editors discuss the rise of TV ads for specialty drugs, signs of life in the biotech IPO scene, and the case for Intercept Pharmaceut...
Pharma's day on the Hill, biotech's paucity of M&A, and the gathering storm of biosimilars
Fierce editors discuss a bizarre congressional hearing, how biotech's slump affects the buyout climate, and a major development in the world...
Gilead's wide-open future, biotech's long winter, and Sanofi's ongoing makeover
Fierce editors discuss the future of Gilead Sciences, biotech's continued slump on Wall Street, and the latest move in Sanofi's efforts to r...
Shire's byzantine Baxalta pursuit, biotech's pragmatic winter and Valeant's CEO shakeup
Fierce editors discuss Shire's increasingly complicated ambition to acquire Baxalta, the changing climate of biotech venture capital and the...
The burning hole in Gilead's $25B pocket and AbbVie's future in hematology
Fierce editors discuss the discussion around Gilead Sciences' huge cash reserve and the many things the company might buy. Plus, a look back...
Gilead's maxed-out revenue, BioMarin's FDA struggles, and GSK's rock and hard place
In an episode free of Valeant Pharmaceuticals and Martin Shkreli, Fierce editors discuss a Senate investigation into Gilead Sciences' pricin...
The ins and outs of 'Pfizergan,' whatever it is Martin Shkreli's doing and the end of two takeover battles
Fierce editors discuss the long-awaited merger agreement between Pfizer and Allergan, Martin Shkreli's CEO double duty, and the whimpering c...
Sanofi's middling future, Amgen's $10B shopping list, and a novel pharma lawsuit
Fierce editors discuss Sanofi's uninspiring forecast, Amgen's return to high-dollar dealmaking and a lawsuit that accuses a drug company of...
Fraud's not that big of a deal: the Valeant story, according to Bill Ackman
Fierce editors discuss the latest turns in the Valeant Pharmaceuticals saga, the seeming inevitability of a Pfizer-Allergan merger, and Shir...
Valeant's semantic innovation, Pfizer's future and the slow trickle of biotech IPOs
Fierce editors discuss a fascinating Valeant Pharmaceuticals conference call, Pfizer's desire for a big buyout and the creaky world of biote...
Doomsdays for Valeant, Biogen and biotech VC
Fierce editors discuss a rough day for Valeant Pharmaceuticals and Biogen, plus the changing in winds in biotech venture capital.
Lilly's latest pipeline peril, Mylan's M&A broken record, and German Merck's big rebrand
Fierce editors discuss a major blow to Eli Lilly's late-stage pipeline, Mylan's ongoing courtship of Perrigo, and Merck KGaA's big push to d...
Biotech's Wall Street malaise, Valeant's Washington woes, and immuno-oncology's primetime slot
Fierce editors discuss another rough week for biotech stocks, Valeant Pharmaceuticals' doggedness in the face of congressional inquiry, and...
Valeant feels the Bern, biotech buckles on Wall Street, and Bristol-Myers turns to Family Feud
Fierce editors discuss how concerns about drug pricing have affected biopharma companies large and small, the latest threat to the biotech b...
John Carroll on Turing Pharma and Martin Shkreli
FierceBiotech's John Carroll discusses his personal experience with the ongoing fallout over Turing Pharmaceuticals' drug pricing and CEO Ma...